The injectable preparation Корвітин (Corvitin) is commonly used in complex hospital settings to provide supportive therapeutic benefits in acute, symptom-driven clinical situations, primarily where significant physiological strain is present. The medicine is applied across therapeutic domains where short-term symptomatic assistance is needed and is considered relevant in contexts involving heightened systemic burden.

This medication is generally used to help manage acute symptom patterns in several severe conditions, including myocardial infarction (heart attack), acute decompensated chronic heart failure, and for supportive use in reperfusion syndrome following major vascular surgeries. It is also relevant for managing certain acute systemic illnesses, such as pneumonia.

“It is commonly used when short-term symptomatic assistance is needed in settings marked by temporary physiological imbalance.”

Quick Fact: Support for Acute Cardiac Distress

Property	Description
Symptom Category	Symptoms linked to organ-specific functional stress
Use Context	Applied in clinical settings that involve acute or unstable symptom patterns
Main Benefit	May offer supportive relief that helps ease the overall symptom burden

The core benefit is that the medication may offer supportive relief that helps ease the overall symptom burden and can assist with supporting the heart during episodes of heightened physiological activity and systemic stress.

Regulatory References

1. Official Instructions for Corvitin (Ministry of Health of Ukraine)

The eligibility for the use of Корвитин (Quercetin lyophilizate for injection) is strictly defined by the medicine’s official regulatory labeling, outlining specific populations and conditions where administration is prohibited or restricted.

Absolute Contraindications

The preparation is absolutely contraindicated in several patient groups. This includes individuals with known hypersensitivity to the active substance quercetin, to any other preparation components, or to preparations possessing P-vitamin activity. A significant comorbidity-based contraindication is the presence of expressed arterial hypotension (marked low blood pressure).

Age and Reproductive Status

Regarding age, Корвитин is contraindicated across the entire pediatric age group, as regulatory documents specify no established experience of use in children. The medicine is primarily established for the adult population.

Specific restrictions apply to reproductive status: use during pregnancy is not recommended. For patients who are breastfeeding, the official regulatory instruction is that breastfeeding must be stopped if the drug is administered during the treatment period. The labeling does not specify absolute prohibitions based on renal or hepatic impairment.

The official regulatory profile for Корвитин (Quercetin) documents several clinically relevant pharmacokinetic and pharmacodynamic interactions. The active substance can significantly alter the systemic exposure of co-administered medicines, largely due to its influence on drug transport and metabolism.

Official Restrictions and Prohibitions

Co-administration with the cardiac glycoside Digoxin is formally noted for avoidance or as a contraindication due to potential alteration of Digoxin exposure. Furthermore, serious interaction warnings are documented for the combination with the P-glycoprotein (P-gp) substrates Topotecan and Everolimus, where regulatory guidance recommends to avoid or use an alternate drug.

Pharmacokinetic Interactions

Primary pharmacokinetic interactions involve the documented inhibition of key cellular drug transporters, including P-gp and OATP. The substance also alters the metabolism of medicines that are substrates for several Cytochrome P450 (CYP) enzymes (e.g., CYP2C8, CYP3A4). This inhibition can result in increased plasma levels and effects of substrates such as Rosuvastatin, Quetiapine, and Cyclosporine.

Pharmacodynamic Interactions

An established pharmacodynamic interaction with anticoagulants, specifically Warfarin, may lead to additive effects that increase the risk of bleeding. Additive blood pressure-lowering or blood sugar-lowering effects are also noted for combination with certain herbal products or supplements that share these functional properties.

The regulatory documentation structures the interaction profile around the dual effects of transport inhibition and metabolic alteration, defining explicit restrictions for combinations where the risk of altered drug exposure is deemed significant.

Core Mechanism: Antioxidant and Cell Membrane Stabilization

The primary mechanism of Корвитин involves antioxidant defense and cell membrane stabilization. The active molecule, Quercetin, acts by directly scavenging Reactive Oxygen Species (ROS) and inhibiting the key enzymes, such as Xanthine Oxidase, that generate these species. This dual action restricts lipid peroxidation, which is the oxidative destruction of the fatty components that form cell and mitochondrial membranes, thereby supporting the maintenance of structural and functional integrity in cells.

Modulating Inflammation and Cell Survival Pathways

The drug's action extends beyond direct scavenging to include the modulation of critical intracellular signaling pathways. It restricts the inflammatory cascade by suppressing the activation of transcription factors like NF-kappa B and specific MAPK enzymes, which reduces the cell’s output of pro-inflammatory mediators. Simultaneously, this signaling interference, alongside the maintenance of mitochondrial function, restricts stress-induced apoptosis (programmed cell death) by engaging internal regulatory signals.

Supporting Microcirculation and Vascular Tone

Корвитин modulates systemic physiological processes by acting on the vascular system. It functions as a modulator that enhances the activity of large-conductance Calcium-activated Potassium channels ( K Ca) in vascular smooth muscle. This K Ca activation leads to vasorelaxation, which alters microvascular resistance and contributes to modified tissue perfusion dynamics.

Corvitin (Корвитин) is characterized by its application as a short-term, acute intervention. The medicine is supplied as a lyophilizate (a freeze-dried powder) and is designed for administration via Intravenous (IV) Drip/Infusion.

Dosing and Frequency Schedule

The medicine is applied in a tapering schedule, where the standard dose unit is 0.5 g per dose. An initial 1.0 g loading dose is utilized for conditions such as Decompensated Chronic Heart Failure (DCHF). The frequency of administration is highest on the first day, reducing to twice daily and finally once daily to conclude the course. The overall regimen is a short-term course, typically lasting 5 days, with a possible extension up to 10 days for acute ischemic stroke.

Preparation and Administration Requirements

The lyophilizate involves a precise, two-step dilution procedure performed immediately prior to use. The powder is first dissolved using 15 ml of 0.9% Sodium Chloride solution, and this solution is then added to a final volume of 50 to 100 ml of the same 0.9% Sodium Chloride diluent. The final solution is delivered as a slow IV drip over a duration of 15 to 20 minutes and is not mixed simultaneously with other medicinal solutions in the same line.

Age-Group Restriction

Corvitin is not recommended for use in children and adolescents under 18 years as there is a lack of clinical experience regarding this population group.

Research Evidence / Overview of Studies for Корвитин

Evidence for Use in Acute Cardiac Distress and Injury

The primary clinical research for the injectable form of Корвитин has focused on examining conditions associated with acute or disruptive episodes, specifically Acute Myocardial Infarction (heart attack) and related events like acute heart failure. This evidence base consists mainly of Prospective Randomized Open-Label Trials and Randomized Controlled Pilot Studies conducted in clinical settings.

The research examined outcomes monitoring physiological strain or stress in adult populations following a severe cardiac event. Research specifically evaluated outcomes related to the mass of potentially damaged myocardium using cardiac biomarkers. Furthermore, research included the evaluation of anatomical outcomes such as Left Ventricular (LV) cavity remodeling and measured factors related to complications of reperfusion injury.

The findings describe patterns observed in studies during the acute treatment period. Data suggest patterns related to the cardiac injury markers measured over the initial acute days of the study period. Research also reported changes measured regarding LV remodeling in the studied groups. Research contributes to the understanding of short-term changes observed in specific, controlled settings.

Long-Term Studies and Follow-up

Research exploring the long-term effects of Корвитин is limited. The clinical trials that was evaluated in these conditions associated with acute or disruptive episodes primarily focused on the immediate acute phase of treatment.

As a result, follow-up durations were limited to short-term observation windows, typically lasting only a few days after the initial event. Therefore, long-term effects are not fully characterized, and there is limited information for long-term outcomes or the durability of the observed patterns over extended periods.

Evidence in Specific Patient Populations

The core clinical research for the medicine was evaluated in adults presenting with Acute Coronary Syndrome. Specific patient subgroups, such as those with concurrent Acute Heart Failure and reduced heart function, were included in the research.

However, the results apply only to the populations studied, which were typically adults in acute hospital settings. Data for certain groups remain insufficient. For instance, there is limited clinical trial information that research describes the use of the medicine in children or in older adults without the acute cardiac conditions that were specifically examined.

Research Gaps and Areas of Uncertainty

The evidence includes trials that were often characterized by small sample sizes and open-label protocols. The existing evidence is generally limited by study scope, and data available do not support definitive conclusions.

Due to these limitations, certainty remains low regarding wide-ranging patient patterns. Findings describe group patterns, not personal outcomes. Research contributes context but not individual predictions, and more extensive comparative research appears to be needed to fully characterize the evidence base.

Key Studies & References

1. Official Instructions for Corvitin (Корвитин) from the Ministry of Health of Ukraine (Regulatory Document)

Common questions about Корвитин (FAQ)

Q: How often does the drug cause an allergic reaction, according to studies?

Official regulatory documents identify hypersensitivity (an allergic reaction) to the active substance, Quercetin, or any of the other components as a reason not to use the medicine. However, these documents do not typically provide a defined frequency rate, but rather focus on the contraindication.

Q: How long can the side effects of Корвитин potentially last?

The medicine is administered as a short-term, acute intervention. Reported side effects, such as headaches or tingling sensations, have been noted in reports to resolve after the treatment course was completed. The duration of side effects is usually consistent with the acute nature of the drug’s use.

Q: Is it okay to use Корвитин if I have a history of heart rhythm issues?

Official product information does not list a history of heart rhythm issues (arrhythmias) as a formal contraindication. However, the use of Корвитин is prohibited in patients with expressed arterial hypotension (marked low blood pressure) and is restricted when used with the cardiac medicine Digoxin. The decision regarding use in patients with pre-existing heart conditions requires assessment by a healthcare professional.

Q: Does Корвитин interact with over-the-counter pain relievers like NSAIDs?

Official drug labels list potential interactions based on the medicine's ability to inhibit certain enzymes (like CYP450) and transporters (P-gp). The risk of interaction with a specific pain reliever, such as an NSAID, depends on whether that pain reliever is a substrate for the affected enzyme or transporter. Information regarding all co-administered medicines should be reviewed from the official labeling.

Q: Are there any general food or diet restrictions mentioned when using Корвитин?

According to the official regulatory documents, there are no specific food or diet restrictions noted for the intravenous administration of Корвитин.

Q: What happens if I use Корвитин with beta-blockers?

The regulatory profile for Корвитин highlights its potential to influence drug metabolism and transport pathways, specifically involving P-glycoprotein and CYP450 enzymes. The effect on a specific beta-blocker would depend on whether that beta-blocker is processed by these same inhibited pathways. This requires a specific analysis by a pharmacist or healthcare provider.

Q: What is the typical duration of action for a single dose of Корвитин?

The duration of the drug’s systemic presence is generally determined by its terminal half-life, a key value documented in the official pharmacokinetic section of the regulatory label. This value is used by healthcare professionals to determine dosing frequency and the overall length of the acute treatment course.

Q: Can the infusion speed of Корвитин affect its side effects?

The official administration instructions require the medicine to be delivered as a slow intravenous drip over a precise time window, typically 15 to 20 minutes. This strict timing is specified to ensure proper administration and implies that deviating from the required speed may impact the medicine's overall safety profile.

Q: Is it possible to receive too much Корвитин?

Yes. Official regulatory documents include safety information on high-dose intravenous use, noting the potential for nephrotoxicity (kidney toxicity). Regulatory information indicates that immediate medical assessment is advised in case of suspected overdose.

The storage and disposal of Корвитин (Quercetin lyophilizate) must adhere strictly to the conditions specified in the official regulatory labeling.

Storage Requirements

The unopened vial of lyophilized powder must be stored in its original packaging at a temperature not exceeding 25 °C. The product is required to be kept in a dry, light-protected place and must remain out of the reach of children.

Stability After Preparation

Because it is an injectable form, the solution's stability after reconstitution is limited:

• The prepared solution is usable for 12 hours if refrigerated (2 °C to 8 °C).
• At 25 °C, stability is 12 hours when diluted in 50 mL of 0.9% sodium chloride solution, but reduces to 6 hours when diluted in 100 mL.

Disposal Instructions

Any unused, expired, or partially used solution must be discarded. Disposal should be carried out according to local regulatory requirements for pharmaceutical waste. If local instructions are unavailable, general government guidance recommends discarding the medicine in the household trash after mixing it with an undesirable substance.